BHCM
KRYS icon

Brevan Howard Capital Management’s Krystal Biotech KRYS Stock Holding History

Brevan Howard Capital Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,902
Closed -$715K – 2315
2025
Q4 		$715K Buy
+2,902
New +$611K 0.01% 920
2025
Q1 		– Sell
-1,396
Closed -$219K – 1318
2024
Q4 		$219K Sell
1,396
-698
-33% -$124K ﹤0.01% 885
2024
Q3 		$381K Buy
+2,094
New +$404K ﹤0.01% 768
2024
Q2 		– Sell
-14,127
Closed -$2.51M – 1238
2024
Q1 		$2.51M Buy
+14,127
New +$1.96M 0.02% 128

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Brevan Howard Capital Management's KRYS Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Krystal Biotech (KRYS) in Q1 2026, closing a stake of 2,902 shares — an estimated $715K sold.

Brevan Howard Capital Management first reported a position in KRYS in Q1 2024 and held it in 4 quarters. The position peaked at $2.51M in Q1 2024. 367 funds tracked by Wall St. Rank hold KRYS as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Krystal Biotech position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 2,902 Krystal Biotech shares in Q1 2026, an estimated $715K.
  • Brevan Howard Capital Management first reported a position in Krystal Biotech in Q1 2024 and held it in 4 quarters.
  • Brevan Howard Capital Management's Krystal Biotech position peaked at $2.51M in Q1 2024.
  • 367 funds tracked by Wall St. Rank held Krystal Biotech as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.